The prevaccination antibody concentrations against tetanus toxoid were similar in the HIV-infected and healthy adults

The prevaccination antibody concentrations against tetanus toxoid were similar in the HIV-infected and healthy adults. irrespective of their CD4+ T-lymphocyte counts. In human immunodeficiency virus (HIV)-infected individuals the amount of antibodies formed after vaccination with T-cell-dependent recall antigens, such as tetanus toxoid, is impaired in proportion to the number of CD4+ T cells and to the in vitro proliferative response of T lymphocytes to anti-CD3 monoclonal antibodies (7, 8). Protection against tetanus will depend on the total amount of antibodies, the subclass distribution, and the avidities of the antibodies that are formed. Avidity reflects the combined functional affinities of antibodies formed during a polyclonal humoral immune response and is considered to be a parameter for the efficacy of the antibodies DPP4 at eliminating or neutralizing the antigen (12). The aim of the present study was to investigate whether, in addition to the concentration of antibodies, the subclass distribution and the avidity of the antibodies formed by HIV-infected RN-1 2HCl individuals after booster vaccination are affected. (This study was presented in part at the 35th Annual Meeting of the Infectious Diseases Society of America, San Francisco, Calif., 13 to 16 September 1997.) MATERIALS AND METHODS In an earlier study (8) we vaccinated 48 HIV-infected adults and 16 healthy controls with DTPol (National Institute of Public Health and Environmental Protection, Bilthoven, The Netherlands), which contains diphtheria toxoid, tetanus toxoid (5 flocculation units), and inactivated poliovirus types 1, 2 and 3. This vaccination was considered to be a booster vaccination since all adult individuals had been vaccinated in the past, most of them during infancy and childhood, according to the national vaccination program for children in The Netherlands, and some of them had received booster vaccinations later in life. The total immunoglobulin G (IgG) anti-tetanus toxoid antibody concentrations before and 30 days after this revaccination were reported previously (8). For the present study we selected 24 HIV-infected individuals and 5 healthy controls from the population from the study described above. Informed consent was obtained from all individuals. The criteria for inclusion were a prevaccination anti-tetanus toxoid IgG antibody concentration of 0.01 arbitrary units/ml (0.05 g/ml) and the ability to mount a humoral response to tetanus toxoid, i.e., a 1.25-fold increase in the IgG anti-tetanus toxoid concentration after revaccination (4). Thirteen of 27 HIV-infected individuals with peripheral blood CD4+ T-lymphocyte counts of <200 106/liter (group I) and 11 of 21 HIV-infected individuals with 200 106 CD4+ T lymphocytes/liter (group II) fulfilled the criteria of selection. These individuals did not differ from the nonselected individuals concerning clinical or laboratory parameters, e.g., CD4+ T-lymphocyte counts. Patient characteristics are presented in Table ?Table1.1. In the sera from RN-1 2HCl the selected individuals described above, total IgG, IgG subclasses, and IgA anti-tetanus toxoid antibodies were quantified by an antibody-capture enzyme-linked immunosorbent assay (ELISA) (6). In short, the wells of a 96-well polystyrene microtiter plate were coated with tetanus toxoid, blocked with bovine serum albumin, and incubated with twofold serial dilutions of serum samples and standard sera. Total IgG and IgA anti-tetanus toxoid antibodies were measured by the addition of alkaline phosphatase-conjugated goat anti-human IgG (-chain specific) and goat anti-human IgA (-chain specific), respectively (Tago, Burlingame, Calif.). Antibodies in the IgG subclasses were measured by successive incubation with IgG subclass-specific monoclonal antibodies (anti-IgG1, MH 161-1 [CLB, Amsterdam, The Netherlands]; anti-IgG2, 35-1-27-2 [TNO, Leiden, The Netherlands]; anti-IgG3, NI 86 [Nordic, Tilburg, The Netherlands]; anti-IgG4, NI 315 [Nordic]), followed by incubation with alkaline phosphatase-conjugated rabbit anti-mouse Ig (Dakopatts, Glostrup, Denmark). After incubation with substrate (< 0.05; Bonferroni-adjusted test). RN-1 2HCl TABLE 1 Demographic parameters, CD4+ T-lymphocyte counts, and stage of HIV infection of study?participants test of logarithmically normalized values) (Table ?(Table2;2; Fig. ?Fig.1). 1). TABLE 2 Anti-tetanus-toxoid antibody concentrations = 13) and 200 106/liter (group II; = 11) and healthy controls (group C; = 5).? bFI, fold increase in concentration is expressed as the ratio RN-1 2HCl of the postvaccination concentration to the prevaccination concentration.? cP < 0.05 compared with group II and controls.? dP < 0.05 compared with group II.?.